Indapta Therapeutics to Highlight its g-NK Cell Platform for the Treatment of Cancer and Autoimmune Disease in a Plenary Session at New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference
Indapta Therapeutics Awarded $4.5 Million by CPRIT to Advance Clinical Development of its Allogenic Natural Killer Cell Therapy
Indapta Therapeutics Receives U.S. FDA Fast Track Designation for IDP-023
Indapta Therapeutics Announces First Patients Treated with IDP-023
Indapta Therapeutics has announced plans to begin a Phase I trial of an allogeneic natural killer (NK) cell therapy, IDP-023, to treat multiple myeloma and lymphoma patients.
Indapta Therapeutics Names Moya Daniels, Senior Vice President of Regulatory, Quality and Clinical Operations